Business
Bionano Genomics Announces 2022 Symposium Featuring Four Consecutive Days of OGM Presentations and Live Panel Discussions Delivered by 25 Different Customers Across a Wide Range of Genetic Disease and Cancer Applications
SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced its 2022 Symposium featuring four consecutive days of OGM presentations delivered by 25 different customers worldwide across a wide range of genetic diseases and cancer applications. The Symposium will take place virtually from January 10 to 13, 2022. During these four days, customers will showcase their latest research findings using OGM in constitutional cytogenomics, hematologic malignancies, solid tumors, and in combination with next-generation sequencing (NGS). Each day will feature oral customer presentations, a live panel with Q&A and a scientific poster exhibit within the virtual exhibition hall. Last year’s Symposium was a landmark event for Bionano, which highlighted the utility of OGM for constitutional and cancer cytogenomics applications with over 4,500 registered attendees. Bionano expects the 2022 Symposium to be more impactful, featuring a broader range of applications being covered and the inclusion of a day of presentations dedicated to demonstrating the benefits of combining OGM and NGS, which can provide a comprehensive analysis of the genome from single-base variants to full chromosomes. “At Bionano, we are working to transform the way the world sees the genome,” said Erik Holmlin, PhD, President and CEO of Bionano Genomics. “Symposium is our platform for the community of OGM users to describe its utility and how it can be integrated with other genome analysis tools to reveal more answers for genetic disease and cancer research applications. We are impressed with the progress that this community has made in applying OGM in their institutions and spreading the word of its potential value in clinical and translational research.” “Since Symposium was last held, we believe our customers around the world have made tremendous progress with the implementation of our Saphr system across a broad range of clinical research applications for consolidating traditional cytogenetics workflows to OGM as well as demonstrating its utility in combination with NGS,” said Alka Chaubey, FACMG, PhD, Chief Medical Officer at Bionano. “Symposium attendees have an opportunity to learn f...